Leo Pharma (Denmark)

Recent papers from Leo Pharma (Denmark)

1. Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect ComparisonDermatology and Therapy · 2026
2. Peripheral Immune Modulation in Atopic Dermatitis During Dupilumab or Baricitinib Treatment Is Limited, as Assessed by Proteomic, Transcriptomic, and Torque Teno Virus AnalysesInternational Journal of Molecular Sciences · 2026
3. Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic DermatitisDermatology and Therapy · 2026
4. Delgocitinib cream formulation demonstrates a dose-dependent response in adults with mild to severe atopic dermatitis: results from an 8-week randomised Phase IIb trialBritish Journal of Dermatology · 2026
5. Clinical trial exit interviews in patients with moderate-to-severe chronic hand eczema: perspectives on disease burden and treatment experiences with delgocitinib cream in the phase III DELTA 1 trialSkin Health and Disease · 2026
6. Imaging-guided tape stripping reveals consistent stratum corneum profiling of disease severity and treatment-responsive molecular features in pediatric atopic dermatitisJournal of Dermatological Science · 2026
7. Below or Above 1.4 mmol/L? – Low-density Lipoprotein Cholesterol Levels During and After Incident Myocardial Infarction in DenmarkMayo Clinic Proceedings · 2026
8. A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”Dermatology and Therapy · 2026
9. Quantification of Stress- and Resistance-Related Metabolites in Barley Leaves ( Hordeum vulgare L.) Infected with Bipolaris sorokiniana via UHPLC-MS/MS MRMJournal of Agricultural and Food Chemistry · 2026
10. Delgocitinib cream for adolescents with moderate to severe chronic hand eczema (DELTA TEEN): a multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Child & Adolescent Health · 2026
11. The Inflammatory Response in the Murine Ovalbumin‐Induced Skin Inflammation Model Is Robust Despite Major Gut Microbiota DifferencesClinical and Translational Science · 2026
12. A Refined Method for Fecal Microbiota Transplantation Using NutellaClinical and Translational Science · 2026
13. Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 TrialDermatology and Therapy · 2026
14. Validation of Quality Indicators for Medication Handling in Residents under Municipality CareResearch in Social and Administrative Pharmacy · 2026
15. Treatment Patterns in Chronic Hand Eczema in the US    Results from the RWEAL-US Medical Chart ReviewSKIN The Journal of Cutaneous Medicine · 2026
16. The Multifactorial and Heterogenous Nature of Chronic Hand Eczema Seen in Clinical Practice in the United States    Results from the RWEAL-US StudySKIN The Journal of Cutaneous Medicine · 2026
17. Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial.2026
18. Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 TrialDermatology and Therapy · 2026
19. Preimmunization of SPF Mice With Capsid Virus‐like Particle Has no Effect on CD8 ⁺ Immune Memory and Skin Inflammation in an Ovalbumin‐Induced Dermatitis ModelClinical and Translational Science · 2026
20. Optimization of protein extraction from skin tape strips for biomarker assessmentScientific Reports · 2026